Turnstone Biologics (NASDAQ:TSBX) Trading 4.2% Higher

Turnstone Biologics Corp. (NASDAQ:TSBX)’s stock price shot up 4.2% during trading on Friday . The company traded as high as $2.76 and last traded at $2.72. 362,685 shares were traded during mid-day trading, an increase of 107% from the average session volume of 175,186 shares. The stock had previously closed at $2.61.

Turnstone Biologics Stock Up 4.2 %

The company has a fifty day moving average of $3.23 and a two-hundred day moving average of $2.75.

Turnstone Biologics (NASDAQ:TSBX) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.13. On average, equities analysts anticipate that Turnstone Biologics Corp. will post -3.34 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new stake in Turnstone Biologics during the third quarter worth about $74,000. FMR LLC acquired a new stake in shares of Turnstone Biologics during the 3rd quarter worth approximately $11,151,000. Eventide Asset Management LLC acquired a new position in Turnstone Biologics during the 3rd quarter valued at approximately $2,791,000. Sectoral Asset Management Inc. bought a new position in Turnstone Biologics during the 3rd quarter worth $2,040,000. Finally, Citigroup Inc. acquired a new stake in Turnstone Biologics in the third quarter worth $30,000. 52.51% of the stock is currently owned by institutional investors.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.